arrow
W

William Jacot

Montpellier University
H指数:51
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort

与转移性乳腺癌一线抗HER2为基础治疗中表现出非凡疗效相关的临床特征:来自ESME国家队列的真实世界数据

Breast
IF7.9
2026-10-130
OA
Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

人表皮生长因子受体2低表达、激素受体阳性转移性乳腺癌的化疗结局:来自法国多中心ESME数据库的见解

Breast
IF7.9
2026-09-270
OA
Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer

早期乳腺癌患者中芳香化酶抑制剂诱导的关节痛预测模型的开发与验证

2026-08-180
PRE
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study
2026-06-240
OAAI
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial

利用高灵敏度ctDNA检测方法在早期乳腺癌中追踪结构变异,可预测新辅助治疗后的复发:多中心ALIENOR试验

2026-06-040
OAAI
Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women

老年转移性三阴性乳腺癌患者的特征、治疗及生存情况:基于ESME mBC真实世界全国队列研究,并与年轻女性进行比较

2026-05-220
OAAI
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

HER2阴性低表达雌激素和孕激素受体转移性乳腺癌患者的特征和结局:多中心ESME队列研究

2026-05-180
OAAI
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort

老年与年轻HR阳性HER2阴性转移性乳腺癌女性患者真实世界多中心法国ESME队列中的近期治疗与生存趋势

2025-12-050
PRE
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康在HER2低表达转移性乳腺癌中的应用:DESTINY-Breast04随机三期试验的长期生存分析

2025-10-080
OAAI
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

CDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效:ESME-MBC队列研究

2025-09-170
PREAI
Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study

乳腺癌病史患者与未暴露女性:一项前瞻性暴露-未暴露队列研究中的受孕时间

2025-07-300
OA
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications

乳腺癌脑转移瘤及其配对原发肿瘤的回顾性真实世界队列基因表达谱分析,识别出具有潜在治疗意义生物学变化

2025-07-230
PREAI
Temporal evolution of breast cancer brain metastases treatments and outcomes
2025-02-200
OA
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features

三级淋巴结构在三阴性乳腺癌中的预后价值: 肿瘤微环境和临床病理特征的综合分析

2024-12-120
OAAI